ABBOTT LABORATORIES — Director's Dealing 2021

May 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-04-30

Reporting Person: Watkin Jared (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-30	Common shares without par value	S	9533	$120.016	Disposed	59783	Direct
2021-04-30	Common shares without par value	M	17043	$44.40	Acquired	76826	Direct
2021-04-30	Common shares without par value	M	68000	$59.94	Acquired	144826	Direct
2021-04-30	Common shares without par value	S	85043	$119.8879	Disposed	59783	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-30	Option (right to buy)	$44.40	M	17043	Disposed	2027-02-16	Common Shares (17043)	Direct
2021-04-30	Option (right to buy	$59.94	M	68000	Disposed	2028-02-15	Common Shares (68000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	602	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.0103 to $120.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.38 to $120.13, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Balance in the Abbott Laboratories Stock Retirement Trust as of April 30, 2021.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.